Engaging American Indians in cancer genome sequencing

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial focuses on developing culturally appropriate strategies to engage and recruit American Indians from Southwestern Tribal Nations for cancer genome sequencing. It aims to understand the genetic changes that lead to higher cancer rates in this population by directly involving cancer patients, survivors, and community advisors in the research process. The study will collect tumor samples and relevant data while providing participants with genomic results and access to counseling resources. The goal is to enhance prevention and treatment strategies for cancer among American Indians in the Southwest.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* The PE-CGS Research Center is only recruiting and sequencing tumors for adult-onset cancers (patients and survivors) among the American Indian Tribes, Nations, and Pueblos of New Mexico and adjacent states
* Male or female adults (18 years) or older
* Cancer patient undergoing active treatment or a cancer survivor
* Self-identify as American Indian

Exclusion Criteria:

* Cognitively impaired
* Adults unable to consent for themselves
* Individuals who are not yet adults
* Prisoners

Where it's running

• University of New Mexico Comprehensive Cancer Center
  Albuquerque, New Mexico, United States Recruiting

Study contacts

• Principal investigator: Cheryl Willman, MD — University of New Mexico Comprehensive Cancer Center
• Study coordinator: Andrew Sussman, PhD
• Email: ASussman@salud.unm.edu
• Phone: (505) 272-4077

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• MK-2010 with Sac-TMT in advanced solid tumors

  This study tests MK-2010 combined with sacituzumab tirumotecan (sac-TMT) to see if it can help people with advanced solid tumors.

  Recruiting at 4 sites Phase 2 Merck Sharp & Dohme LLC · San Antonio, Texas and 3 other locations · NCT07785609

• Belzutifan in adolescents with solid tumors

  This study tests belzutifan in teenagers whose solid tumors can't be removed by surgery or have spread.

  Recruiting at 10 sites Phase 2 Merck Sharp & Dohme LLC · Iowa City, Iowa and 9 other locations · NCT07700758

• Ifinatamab Deruxtecan in kids with relapsed or refractory solid cancers

  This study tests whether I-DXd can help children whose solid tumors have come back or not responded to previous treatments.

  Recruiting at 35 sites Phase 1/2 Merck Sharp & Dohme LLC · Los Angeles, California and 34 other locations · NCT07630974

• MK-4884 safety in advanced solid tumors

  This early-phase study tests different doses of MK-4884 to see if it is safe and tolerable for adults with certain advanced solid cancers.

  Recruiting at 10 sites Phase 1 Merck Sharp & Dohme LLC · St Louis, Missouri and 9 other locations · NCT07600749

• PET scan targeting CDH3 for lung tumors

  This will test whether a new PET imaging agent called 68Ga-TOI-1 that targets CDH3 can better detect and stage lung tumors and help tell malignant from benign pulmonary nodules in adults with suspected or confirmed non-small cell lung cancer.

  Recruiting Peking University People's Hospital · Beijing, Beijing Municipality · NCT07487883

• Dabrafenib and trametinib for rare cancers with BRAF V600 mutations

  This arm tests whether dabrafenib and trametinib can help adults, children, and teens with cancers that have a BRAF V600 mutation.

  Recruiting at 15 sites Phase 2/3 Cancer Research UK · Belfast and 26 other locations · NCT07440290

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.